Avid Bioservices Inc (CDMO)

[sunstar]

biopharm, Gilead was willing to pay $11 billion for, essentially, one phase2 Hep C drug. Maybe one of the factors that might be considered is company culture, when it comes to foresight and positioning for competitiveness in PharmaLand.

That daring Pharmasset acquisition has certainly served them well. In the three years since GILD made that move, their share price has appreciated by 425%, and they gave their investors a 2 for 1 forward split as well. Also, GILD’s annual revenues are up by about $3 billion over that period. And, they have had a huge market cap boost. Take a look at the GILD 3 year chart.

Might a pharma like GILD now decide that it wanted to compete in immuno-oncology, and double that previous expenditure to $22 billion for, not just one drug, but a full platform of upstream immuno oncology mAbs capable of treating a whole host of serious cancer indications?

Would Peregrine be willing to accept an offer like that?

Does Gilead have the corporate pharma culture that could serve the continued development of anti-PS tech going forward?

Maybe Gilead is one of the companies that is collaborating with PPHM. They certainly seem to have a Vision.

IMO

sunstar